Current Report Filing (8-k)
November 08 2022 - 04:13PM
Edgar (US Regulatory)
0001448431 false 0001448431 2022-11-08
2022-11-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
November 8, 2022
OptimizeRx Corporation
(Exact name of registrant as specified in charter)
Nevada
|
|
001-38543
|
|
26-1265381
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number) |
|
(IRS Employer
Identification No.)
|
400 Water Street,
Suite 200,
Rochester,
MI
|
|
48307
|
(Address of principal executive
offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code:
248.651.6568
Not
Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each
class |
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered |
Common Stock, $0.001 Par Value |
|
OPRX |
|
The
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 2.02 Results of Operations and Financial
Condition.
On November 8, 2022, OptimizeRx Corporation issued a press release
announcing its financial results for the third quarter ended
September 30, 2022. A copy of the press release is furnished with
this Current Report on Form 8-K as Exhibit 99.1 and is incorporated
herein by reference.
The information in this Item
2.02 and Exhibit 99.1 attached hereto are furnished and shall not
be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of that section, nor shall such
information be deemed incorporated by reference into any filing
under the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in such
filing.
Item 9.01. Financial Statements and
Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
OPTIMIZERX
CORPORATION |
|
|
Date: November 8,
2022 |
By: |
/s/ Edward Stelmakh |
|
|
Name: |
Edward Stelmakh |
|
|
Title: |
Chief Financial
Officer |
2
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From May 2023 to Jun 2023
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Jun 2022 to Jun 2023